Technology based specialty pharmaceutical company Impax Laboratories has said that beginning July 1, 2009, Impax Pharmaceuticals, the company's specialty brand products division will co-promote Wyeth's Pristiq.

Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI) as a treatment for adult patients with major depressive disorder (MDD).

As previously announced, Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists.

 Impax will receive a fee for each detail delivered. Other terms of the agreement were kept confidential and not disclosed.

Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform.